Medtronic (MDT) Offering Possible 31.23% Return Over the Next 15 Calendar Days

Medtronic's most recent trend suggests a bearish bias. One trading opportunity on Medtronic is a Bear Call Spread using a strike $105.00 short call and a strike $110.00 long call offers a potential 31.23% return on risk over the next 15 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $105.00 by expiration. The full premium credit of $1.19 would be kept by the premium seller. The risk of $3.81 would be incurred if the stock rose above the $110.00 long call strike price.

The 5-day moving average is moving down which suggests that the short-term momentum for Medtronic is bearish and the probability of a decline in share price is higher if the stock starts trending.

The 20-day moving average is moving down which suggests that the medium-term momentum for Medtronic is bearish.

The RSI indicator is at 39.69 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Medtronic

Medtronic Nabs FDA Approval For Nerve Monitoring System
Thu, 29 Oct 2020 13:05:49 +0000
Medtronic plc (MDT) has announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance of the NIM Vital nerve monitoring system, which enables physicians to identify, confirm, and monitor nerve function to help reduce the risk of nerve damage during head and neck surgery.According to MDT, the NIM Vital system uses proprietary technology to provide detailed intraoperative nerve condition data that informs surgical strategy, increases operative efficiency and precision, and helps protect patients’ quality of life.The company also announced that it has further ramped up its ear nose and throat (ENT) portfolio with the recent acquisition of privately-held Ai Biomed Corp., maker of the PTeye parathyroid detection system. The probe-based system is designed to help confirm parathyroid tissue identified visually by the physician during thyroid surgery.“The addition of these two technologies builds on our 20-year legacy of providing innovative solutions that assist surgeons during critical head and neck procedures,” said Vince Racano, VP of Medtronic’s ENT business.“By offering these complementary technologies – the NIM Vital system to protect crucial nerves and the PTeye system to help confirm parathyroid tissue identified visually by the surgeon – we’re helping physicians address two of the most common challenges during these procedures.”The acquisition of Ai Biomed Corp. is the seventh in a series of tuck-in acquisitions that Medtronic has made in 2020. MDT states that the revenue and earnings contribution is expected to be immaterial to the Medtronic ENT business in the first year and accretive thereafter.Shares in the medical device stock are down 10% year-to-date, but the stock scores a bullish Strong Buy consensus from the Street. That’s with 18 recent buy ratings, vs 3 hold ratings and 1 sell rating.Meanwhile the average analyst price target of $120 indicates 17% upside potential from current levels.“Between delays in the development of its robotic system or the stumbles in Diabetes, MDT will still need to prove that it can be a consistent 5% grower, but with MDT’s markets growing at 5% roughly, M&A should provide a cushion to the top-line” comments BTIG analyst Ryan Zimmerman.He reiterated his buy rating on MDT with a $119 price target arguing that: “Investors should not expect incrementally more return to the bottom line as the focus will be top-line growth reinvestment, but in a market where top-line growth is highly rewarded, we think this strategy makes sense.” (See MDT stock analysis on TipRanks).Related News: Gilead Cuts 2020 Guidance As Remdesivir Sales Disappoint Eli Lilly Ends Covid-19 Trial In Hospitalized Patients On Disappointing Data Dexcom Drops 9% As Revenue Beat Fails To Impress Investors More recent articles from Smarter Analyst: * LVMH Agrees To Buy Tiffany At Lower Price; Street Sticks To Hold * Moderna Scores $1.1B From Covid-19 Vaccine Deposits; Shares Rise 3% * Etsy Beats Q3 Estimates On Robust Online Demand * Novartis Snaps Up Vedero Bio In $280M Deal; Street Says Buy

Medtronic Expands ENT Portfolio with FDA Clearance of NIM Vital™ Next Generation Intraoperative Nerve Monitoring System and Acquisiton of Ai Biomed Corp.
Thu, 29 Oct 2020 11:00:00 +0000
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance of the NIM Vital™ nerve monitoring system, which enables physicians to identify, confirm, and monitor nerve function to help reduce the risk of nerve damage during head and neck surgery.1 The NIM Vital system uses proprietary technology to provide detailed intraoperative nerve condition data that informs surgical strategy,2 increases operative efficiency and precision,3 and helps protect patients' quality of life.4

University of British Columbia's energy-efficiency initiative receives a boost through the Low Carbon Economy Fund
Tue, 27 Oct 2020 22:00:00 +0000
VANCOUVER, BC, Oct. 27, 2020 /CNW/ – Canadians from coast to coast to coast are taking action to tackle climate change in their communities.

Medtronic Venous Stent Receives U.S. FDA Approval to Treat Venous Outflow Obstruction
Mon, 26 Oct 2020 14:00:00 +0000
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval for the Abre™ venous self-expanding stent system. This device is indicated for use in the iliofemoral veins in patients with symptomatic iliofemoral venous outflow obstruction, also known as deep venous obstruction.

West Pharmaceutical ESG Rating Upgraded; WST Stock Hits Record Highs
Mon, 26 Oct 2020 12:00:37 +0000
West Pharmaceutical reviewed its compliance and ethics program last year so well that a key ESG ratings firm upgraded it to the highest-possible AAA grade, just as WST stock hit new highs.

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.